Quotables
"What, sir, would you make a ship sail against the wind and currents by lighting a bonfire under her deck? I pray you, excuse me, I have not the time to listen to such nonsense."
Napoleon Bonaparte ; When told of the Robert Fulton steamboat
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8168592 | CGRP peptide antagonists and conjugates Disclosed is a composition of matter that involves a CGRP peptide antagonist. A pharmaceutical composition is disclosed that comprises the composition of matter and a pharmaceutically acceptable carrier, which can be configured for administration to a patient. Also ... | 05/01/2012 |
| 8043829 | DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression Disclosed is a composition of matter comprising a ShK toxin peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs... | 10/25/2011 |
| 8008453 | Modified Fc molecules Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry throu... | 08/30/2011 |
| 7910102 | Methods of using conjugated toxin peptide therapeutic agents Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs enc... | 03/22/2011 |
| 7906625 | Humanized anti-amyloid antibody Compositions for treating neurodegenerative or amyloidgenic disorders such as Alzheimer's disease (AD) are provided. More particularly, humanized anti-amyloid-beta antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cel... | 03/15/2011 |
| 7834164 | DNA encoding OSK1 toxin peptide analogs and vectors and cells for combinant expression Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs enc... | 11/16/2010 |
| 7833979 | Toxin peptide therapeutic agents Disclosed is a composition of matter of the formula (X1)a—(F1)d—(X2)b—(F2)e—(X3)c (I) and multimers thereof, in which F | 11/16/2010 |
| 7825093 | Methods of using OSK1 peptide analogs Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs enc... | 11/02/2010 |
| 7820623 | Conjugated toxin peptide therapeutic agents Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs enc... | 10/26/2010 |
| 7803769 | OSK1 peptide analogs and pharmaceutical compositions Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs enc... | 09/28/2010 |
| 7750128 | Modified Fc molecules The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. ... | 07/06/2010 |
| 7750127 | Modified Fc molecules The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. ... | 07/06/2010 |
| 7732399 | Sustained release formulations The present invention relates broadly to the field of sustained release formulations. More specifically, the invention describes compositions and methods relating to formulating proteins and/or peptides with purified gallic acid esters. In one example, the gallic ac... | 06/08/2010 |
| 7662931 | Modified Fc molecules The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. ... | 02/16/2010 |
| 7655765 | Modified Fc molecules The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. ... | 02/02/2010 |
| 7655764 | Modified Fc molecules The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. ... | 02/02/2010 |
| 7645861 | Modified Fc molecules The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. ... | 01/12/2010 |
| 7605120 | Antagonists of the brandykinin B1 receptor The present invention relates to certain biologically active peptides and conjugated peptides which can be used as therapeutics or prophylactics against diseases or conditions linked to B1 as the causative agent. In a preferred embodiment of the invention biological... | 10/20/2009 |
| 7582465 | Beta secretase genes Disclosed are novel genes encoding beta secretase polypeptides. Also disclosed are methods of making and using the polypeptides. ... | 09/01/2009 |
| 7579180 | Beta secretase polypeptides Disclosed are novel genes encoding beta secretase polypeptides. Also disclosed are methods of making and using the polypeptides. ... | 08/25/2009 |
| 7442778 | Modified Fc molecules The present invention concerns molecules and a process in which one or more biologically active peptides are incorporated into an Fc domain. In this invention, pharmacologically active compounds may be prepared by a process comprising (a) selecting at least one pept... | 10/28/2008 |
